Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 3

2(50.0%)

N/A

1(25.0%)

Phase 2

1(25.0%)

4Total

Phase 3(2)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07018700Phase 3Recruiting

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

Role: lead

NCT07018713Phase 3Recruiting

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

Role: lead

NCT06091020Phase 2Completed

A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared With Placebo Injections in Participants Aged 18 Years and Older With Chronic Nerve Pain After Shingles or Nerve Injury

Role: lead

NCT05884528Completed

Assessment of Long-term Clinical Response to BoNT in Cervical Dystonia

Role: lead

NCT06381999Completed

Validity and Inter-rater Reliability for Early Recognition of Spasticity Using the Decision Tree Tool

Role: lead

NCT05943860Not ApplicableCompleted

Efficacy and Tolerability of Pantovigar® Vegan in Female Subjects With Diffuse Hair Loss

Role: lead

All 6 trials loaded